Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bone Biologics (BBLG) Gains from Investment Securities (2016 - 2017)

Bone Biologics (BBLG) has disclosed Gains from Investment Securities for 2 consecutive years, with $412531.0 as the latest value for Q3 2017.

  • On a quarterly basis, Gains from Investment Securities fell 93.52% to $412531.0 in Q3 2017 year-over-year; TTM through Sep 2017 was $412531.0, a 93.52% decrease, with the full-year FY2023 number at -$892693.0, changed N/A from a year prior.
  • Gains from Investment Securities was $412531.0 for Q3 2017 at Bone Biologics, down from $12.7 million in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $12.7 million in Q1 2017 to a low of -$502.0 in Q4 2016.